Global Animal Vaccine Market to Reach US$ 25.1 Billion by 2032, Stimulated by Increasing Demand for Animal-Derived Products

According to the latest report by IMARC Group, titled “Animal Vaccine Market Report by Product (Attenuated vaccines, Inactivated vaccines, Subunit vaccines, Toxoid vaccines, Conjugate vaccines, Recombinant vaccines, DNA vaccines Type), Animal Type (Companion Animal, Livestock Animal), Route of Administration (Subcutaneous, Intramuscular, Intranasal, and Others), and Region 2024-2032,” the global animal vaccine market size reached US$ 13.4 Billion in 2023. Animal vaccines are biological preparations designed to improve the immunity of animals against specific diseases. These vaccines function by stimulating the immune system to recognize the disease agent as a threat, destroy it, and keep a record of it so that the immune system can more easily recognize and combat the pathogen in future encounters. The composition of animal vaccines varies depending on the target disease and animal species. They can include live attenuated organisms, inactivated or killed organisms, or subunits of the pathogen, involving rigorous scientific research and testing to ensure safety and efficacy. Animal vaccines play a critical role in veterinary medicine and animal husbandry, contributing to the health and welfare of both domestic and farm animals. They help control and prevent the spread of infectious diseases, particularly in the agriculture and food production sectors.

Global Animal Vaccine Market Trends:

The increasing prevalence of zoonotic diseases, which are infectious diseases transmittable from animals to humans has heightened awareness about animal health, prompting extensive investment in animal vaccination programs, thereby primarily driving the global market. In addition to this, the flourishing expansion of the livestock sector, driven by rising demand for animal protein, necessitates enhanced disease management in livestock populations to ensure productivity and food safety, strengthening the market growth. Moreover, ongoing advancements in biotechnological research leading to the development of more effective and safer vaccines as well as broadening the range of diseases that can be effectively controlled are aiding in market expansion. At the same time, favorable governmental policies and initiatives promoting animal health and mandating regular vaccinations for certain diseases, are contributing to the market growth. Concurrently, increasing pet ownership across the globe, with a surging number of people adopting pets and showing a willingness to spend on their health and well-being, is boosting the market growth. Besides this, the growing focus on preventive healthcare for animals, supportive initiatives by animal welfare organizations, improved distribution channels, and increasing access to veterinary services are fueling the market growth. Furthermore, the growing international trade of animal products spurring the need for standardized health protocols, including vaccinations, to prevent the spread of diseases across borders is influencing the market growth. Apart from this, the introduction of needle-free injection technologies and oral vaccines making the administration of animal vaccines more efficient and less stressful for animals, are propelling the market forward. Looking forward, the market value is projected to reach US$ 25.1 Billion by 2032, expanding at a CAGR of 7.24% during 2024-2032.

Market Summary:

• Based on the product, the market has been segmented into attenuated, inactivated, subunit, toxoid, conjugate, recombinant, and DNA vaccines. Currently, attenuated vaccines dominate the market, holding the largest share.
• On the basis of the animal type, the market has been categorized as companion animal (dogs and cats), and livestock animals (cattle, pigs, sheep, and others). Between these, livestock animals represent the biggest market segment.
• Based on the route of administration, the market has been classified into subcutaneous, intramuscular, intranasal, and others. Amongst these, the subcutaneous route accounts for the largest market share.
• On a regional basis, the market has been segregated into North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. Presently, North America is the leading market.
• The competitive landscape of the market has also been examined, with some of the key players being C.H. Boehringer Sohn AG & Co. KG, Ceva Sante Animale, Elanco Animal Health Incorporated (Eli Lilly and Company), Hester Biosciences Limited, Hipra S.A., Hygieia Biological Laboratories, Merck & Co. Inc., Phibro Animal Health Corporation, Vaxxinova GmbH (EW Group), Virbae, Zoetis Services LLC, etc.

Report Coverage:

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800